Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study.
The efficacy of dexamethasone therapy for primary respiratory syncytial virus bronchiolitis was studied in a double-blind placebo design in 29 previously healthy infants (median age, 194 days). No significant differences were found between the groups in evolution of respiratory rate, oxygen saturation, clinical score, or pulmonary function tests on day 3.
De Boeck
K
K
Department of Pediatrics, University of Leuven, Belgium.
Van der Aa
N
N
Van Lierde
S
S
Corbeel
L
L
Eeckels
R
R
D000704:Analysis of Variance; D001990:Bronchiolitis, Viral / Q000188:drug therapy*; D003907:Dexamethasone / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D007275:Injections, Intravenous; D007902:Length of Stay; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D012129:Respiratory Function Tests; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D018113:Respiratory Syncytial Virus, Human / Q000302:isolation & purification*
D005938:Glucocorticoids; D003907:Dexamethasone